Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05025_nanopub.RAc5nhSalJ9Wo-pIehsDBfRp04d48nUS-fgH1LZCscuIA#assertion>. }
Showing items 1 to 16 of
16
with 100 items per page.
- drugbank:DB05025 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05025 label "Arimoclomol [drugbank:DB05025]" assertion.
- drugbank:DB05025 seeAlso DB05025 assertion.
- drugbank:DB05025 description "Arimoclomol is an experimental drug compound developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. The orally administered drug is intended to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a neurodegenerative disease with no effective treatment." assertion.
- drugbank:DB05025 identifier "drugbank:DB05025" assertion.
- drugbank:DB05025 title "Arimoclomol" assertion.
- drugbank:DB05025 drugbank_vocabulary:x-pubchemsubstance pubchem.substance:783757 assertion.
- drugbank:DB05025 drugbank_vocabulary:x-pubchemcompound pubchem.compound:208924 assertion.
- drugbank:DB05025 drugbank_vocabulary:x-chemspider chemspider:181020 assertion.
- drugbank:DB05025 drugbank_vocabulary:x-cas cas:289893-25-0 assertion.
- drugbank:DB05025 drugbank_vocabulary:drugbank-id "DB05025" assertion.
- drugbank:DB05025 bio2rdf_vocabulary:x-identifiers.org DB05025 assertion.
- drugbank:DB05025 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05025" assertion.
- drugbank:DB05025 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05025 bio2rdf_vocabulary:identifier "DB05025" assertion.
- drugbank:DB05025 drugbank_vocabulary:x-wikipedia wikipedia:Arimoclomol assertion.